메뉴 건너뛰기




Volumn 122, Issue 22, 2013, Pages 3583-3590

How I treat monoclonal gammopathy of renal significance (MGRS)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENDAMUSTINE; BICARBONATE; BORTEZOMIB; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; PHOSPHATE; RIBAVIRIN; RITUXIMAB; THALIDOMIDE; VITAMIN D;

EID: 84888228292     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-495929     Document Type: Article
Times cited : (253)

References (105)
  • 1
    • 84869779556 scopus 로고    scopus 로고
    • International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant
    • Leung N, Bridoux F, Hutchison CA, et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-4295.
    • (2012) Blood , vol.120 , Issue.22 , pp. 4292-4295
    • Leung, N.1    Bridoux, F.2    Hutchison, C.A.3
  • 2
    • 33750616035 scopus 로고    scopus 로고
    • Dangerous small B-cell clones
    • Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
    • (2006) Blood , vol.108 , Issue.8 , pp. 2520-2530
    • Merlini, G.1    Stone, M.J.2
  • 3
    • 0348022718 scopus 로고    scopus 로고
    • Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits
    • Touchard G, Aucouturier P, Hermine O, Ronco P, eds, Dordrecht, Boston: Kluwer Academic Publishers
    • Touchard G. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. In: Touchard G, Aucouturier P, Hermine O, Ronco P, eds. Monoclonal Gammopathies and the Kidney. Dordrecht, Boston: Kluwer Academic Publishers; 2003:95-118.
    • (2003) Monoclonal Gammopathies and the Kidney. , pp. 95-118
    • Touchard, G.1
  • 4
    • 84888258940 scopus 로고    scopus 로고
    • Monoclonal Gammopathies: Multiple Myeloma, Amyloidosis, and Related Disorders
    • Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, eds, 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins
    • Ronco P, Bridoux F, Aucouturier P. Monoclonal Gammopathies: Multiple Myeloma, Amyloidosis, and Related Disorders. In: Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, eds. Schrier's Diseases of the Kidney 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2013:1710-1765.
    • (2013) Schrier's Diseases of the Kidney , pp. 1710-1765
    • Ronco, P.1    Bridoux, F.2    Aucouturier, P.3
  • 5
    • 0036405058 scopus 로고    scopus 로고
    • Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features
    • Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int. 2002;62(5):1764-1775.
    • (2002) Kidney Int. , vol.62 , Issue.5 , pp. 1764-1775
    • Bridoux, F.1    Hugue, V.2    Coldefy, O.3
  • 6
    • 0037379132 scopus 로고    scopus 로고
    • Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features
    • Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003;63(4):1450-1461.
    • (2003) Kidney Int. , vol.63 , Issue.4 , pp. 1450-1461
    • Rosenstock, J.L.1    Markowitz, G.S.2    Valeri, A.M.3    Sacchi, G.4    Appel, G.B.5    D'Agati, V.D.6
  • 7
    • 0024366205 scopus 로고
    • The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias
    • Gallo G, Picken M, Buxbaum J, Frangione B. The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias. Semin Hematol. 1989;26(3):234-245.
    • (1989) Semin Hematol. , vol.26 , Issue.3 , pp. 234-245
    • Gallo, G.1    Picken, M.2    Buxbaum, J.3    Frangione, B.4
  • 8
    • 54049148697 scopus 로고    scopus 로고
    • Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    • Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143(3):369-373.
    • (2008) Br J Haematol. , vol.143 , Issue.3 , pp. 369-373
    • Lebovic, D.1    Hoffman, J.2    Levine, B.M.3
  • 9
    • 78149282151 scopus 로고    scopus 로고
    • Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
    • Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93-97.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 93-97
    • Bodin, K.1    Ellmerich, S.2    Kahan, M.C.3
  • 10
    • 14844319262 scopus 로고    scopus 로고
    • Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment
    • Nordic Myeloma Study Group
    • Carlson K, Hjorth M, Knudsen LM; Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment. Br J Haematol. 2005;128(5):631-635.
    • (2005) Br J Haematol. , vol.128 , Issue.5 , pp. 631-635
    • Carlson, K.1    Hjorth, M.2    Knudsen, L.M.3
  • 11
    • 36148973115 scopus 로고    scopus 로고
    • Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
    • Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47(12):1466-1475.
    • (2007) J Clin Pharmacol. , vol.47 , Issue.12 , pp. 1466-1475
    • Chen, N.1    Lau, H.2    Kong, L.3    Kumar, G.4    Zeldis, J.B.5    Knight, R.6    Laskin, O.L.7
  • 12
    • 79952126085 scopus 로고    scopus 로고
    • Kidney dysfunction during lenalidomide treatment for AL amyloidosis
    • Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011;26(3):881-886.
    • (2011) Nephrol Dial Transplant , vol.26 , Issue.3 , pp. 881-886
    • Specter, R.1    Sanchorawala, V.2    Seldin, D.C.3
  • 13
    • 20044381304 scopus 로고    scopus 로고
    • Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function
    • SUMMIT/CREST Investigators
    • Jagannath S, Barlogie B, Berenson JR, et al; SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005;103(6):1195- 1200.
    • (2005) Cancer. , vol.103 , Issue.6 , pp. 1195-1200
    • Jagannath, S.1    Barlogie, B.2    Berenson, J.R.3
  • 14
    • 33947201310 scopus 로고    scopus 로고
    • Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study
    • Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604-2606.
    • (2007) Blood , vol.109 , Issue.6 , pp. 2604-2606
    • Chanan-Khan, A.A.1    Kaufman, J.L.2    Mehta, J.3
  • 15
    • 42349108452 scopus 로고    scopus 로고
    • Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study
    • San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4):842-849.
    • (2008) Leukemia. , vol.22 , Issue.4 , pp. 842-849
    • San-Miguel, J.F.1    Richardson, P.G.2    Sonneveld, P.3
  • 16
    • 79955461011 scopus 로고    scopus 로고
    • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study
    • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
    • (2011) Lancet Oncol. , vol.12 , Issue.5 , pp. 431-440
    • Moreau, P.1    Pylypenko, H.2    Grosicki, S.3
  • 17
    • 81155134123 scopus 로고    scopus 로고
    • Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease
    • Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011;155(5):632-634.
    • (2011) Br J Haematol. , vol.155 , Issue.5 , pp. 632-634
    • Ramasamy, K.1    Hazel, B.2    Mahmood, S.3    Corderoy, S.4    Schey, S.5
  • 18
    • 84864375343 scopus 로고    scopus 로고
    • Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
    • Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138(8):1405-1412.
    • (2012) J Cancer Res Clin Oncol. , vol.138 , Issue.8 , pp. 1405-1412
    • Pönisch, W.1    Andrea, M.2    Wagner, I.3
  • 19
    • 0036421605 scopus 로고    scopus 로고
    • The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study
    • Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 2002;20(7-8):904-913.
    • (2002) Cancer Invest. , vol.20 , Issue.7-8 , pp. 904-913
    • Lichtman, S.M.1    Etcubanas, E.2    Budman, D.R.3
  • 20
    • 0036830415 scopus 로고    scopus 로고
    • Treatment of a patient with end-stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis
    • Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol. 2002;71(3):219-222.
    • (2002) Am J Hematol. , vol.71 , Issue.3 , pp. 219-222
    • Jillella, A.P.1    Dainer, P.M.2    Kallab, A.M.3    Ustun, C.4
  • 21
    • 10744232375 scopus 로고    scopus 로고
    • Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics
    • Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77(4):542-548.
    • (2004) Transplantation , vol.77 , Issue.4 , pp. 542-548
    • Vieira, C.A.1    Agarwal, A.2    Book, B.K.3
  • 22
    • 0034584614 scopus 로고    scopus 로고
    • Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
    • San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1(1):28-36.
    • (2000) Hematol J. , vol.1 , Issue.1 , pp. 28-36
    • San Miguel, J.F.1    Lahuerta, J.J.2    Garcia-Sanz, R.3
  • 23
    • 0034799598 scopus 로고    scopus 로고
    • Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    • Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822-829.
    • (2001) Br J Haematol. , vol.114 , Issue.4 , pp. 822-829
    • Badros, A.1    Barlogie, B.2    Siegel, E.3
  • 24
    • 21044439673 scopus 로고    scopus 로고
    • Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure
    • Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75(1):27-33.
    • (2005) Eur J Haematol. , vol.75 , Issue.1 , pp. 27-33
    • Knudsen, L.M.1    Nielsen, B.2    Gimsing, P.3    Geisler, C.4
  • 25
    • 17144398084 scopus 로고    scopus 로고
    • Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation
    • Schrier RW, Parikh CR. Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation. Nephrol Dial Transplant. 2005;20(4):678-683.
    • (2005) Nephrol Dial Transplant , vol.20 , Issue.4 , pp. 678-683
    • Schrier, R.W.1    Parikh, C.R.2
  • 26
    • 77956486044 scopus 로고    scopus 로고
    • A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT
    • Ando M, Mori J, Ohashi K, et al. A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplant. 2010;45(9):1427-1434.
    • (2010) Bone Marrow Transplant , vol.45 , Issue.9 , pp. 1427-1434
    • Ando, M.1    Mori, J.2    Ohashi, K.3
  • 27
    • 84155167437 scopus 로고    scopus 로고
    • Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis
    • Irazabal MV, Eirin A, Gertz MA, et al. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. Am J Hematol. 2012;87(1):51-54.
    • (2012) Am J Hematol. , vol.87 , Issue.1 , pp. 51-54
    • Irazabal, M.V.1    Eirin, A.2    Gertz, M.A.3
  • 28
    • 33748692889 scopus 로고    scopus 로고
    • Immunoglobulin free light chains and solitary plasmacytoma of bone
    • Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979-1983.
    • (2006) Blood , vol.108 , Issue.6 , pp. 1979-1983
    • Dingli, D.1    Kyle, R.A.2    Rajkumar, S.V.3
  • 29
    • 84871772553 scopus 로고    scopus 로고
    • New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes
    • Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
    • (2012) J Clin Oncol. , vol.30 , Issue.36 , pp. 4541-4549
    • Palladini, G.1    Dispenzieri, A.2    Gertz, M.A.3
  • 30
    • 84988241358 scopus 로고    scopus 로고
    • International uniform response criteria for multiple myeloma
    • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(12):1467-1673.
    • (2006) Leukemia. , vol.20 , Issue.12 , pp. 1467-1673
    • Durie, B.G.1    Harousseau, J.L.2    Miguel, J.S.3
  • 31
    • 22844431720 scopus 로고    scopus 로고
    • Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
    • Leung N, Dispenzieri A, Fervenza FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005;46(2):270-277.
    • (2005) Am J Kidney Dis. , vol.46 , Issue.2 , pp. 270-277
    • Leung, N.1    Dispenzieri, A.2    Fervenza, F.C.3
  • 32
    • 84862505358 scopus 로고    scopus 로고
    • Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)
    • Ramirez-Alvarado M, Ward CJ, Huang BQ, et al. Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al). PLoS ONE. 2012;7(6):e38061.
    • (2012) PLoS ONE. , vol.7 , Issue.6
    • Ramirez-Alvarado, M.1    Ward, C.J.2    Huang, B.Q.3
  • 33
    • 17044458969 scopus 로고    scopus 로고
    • Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients
    • Messiaen T, Deret S, Mougenot B, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore). 2000;79(3):135-154.
    • (2000) Medicine (Baltimore) , vol.79 , Issue.3 , pp. 135-154
    • Messiaen, T.1    Deret, S.2    Mougenot, B.3
  • 34
    • 77956149714 scopus 로고    scopus 로고
    • Solid organ transplantation in AL amyloidosis
    • Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010;10(9):2124-2131.
    • (2010) Am J Transplant , vol.10 , Issue.9 , pp. 2124-2131
    • Sattianayagam, P.T.1    Gibbs, S.D.2    Pinney, J.H.3
  • 35
    • 79958113175 scopus 로고    scopus 로고
    • Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
    • Herrmann SM, Gertz MA, Stegall MD, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011;26(6):2032-2036.
    • (2011) Nephrol Dial Transplant , vol.26 , Issue.6 , pp. 2032-2036
    • Herrmann, S.M.1    Gertz, M.A.2    Stegall, M.D.3
  • 36
    • 57849120727 scopus 로고    scopus 로고
    • Heart transplantation in systemic (AL) amyloidosis: A retrospective study of eight French patients
    • Mignot A, Varnous S, Redonnet M, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008;101(9):523-532.
    • (2008) Arch Cardiovasc Dis. , vol.101 , Issue.9 , pp. 523-532
    • Mignot, A.1    Varnous, S.2    Redonnet, M.3
  • 37
    • 79251514326 scopus 로고    scopus 로고
    • Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft
    • Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol. 2011;6(1):122-132.
    • (2011) Clin J Am Soc Nephrol. , vol.6 , Issue.1 , pp. 122-132
    • Nasr, S.H.1    Sethi, S.2    Cornell, L.D.3
  • 38
    • 79958131056 scopus 로고    scopus 로고
    • Renal transplantation in light chain amyloidosis: Coming out of the cupboard
    • Bridoux F, Ronco P, Gillmore J, Fermand JP. Renal transplantation in light chain amyloidosis: coming out of the cupboard. Nephrol Dial Transplant. 2011;26(6):1766-1768.
    • (2011) Nephrol Dial Transplant , vol.26 , Issue.6 , pp. 1766-1768
    • Bridoux, F.1    Ronco, P.2    Gillmore, J.3    Fermand, J.P.4
  • 39
    • 84873098366 scopus 로고    scopus 로고
    • Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance
    • Pinney JH, Lachmann HJ, Sattianayagam PT, et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant. 2013;13(2):433-441.
    • (2013) Am J Transplant , vol.13 , Issue.2 , pp. 433-441
    • Pinney, J.H.1    Lachmann, H.J.2    Sattianayagam, P.T.3
  • 40
    • 21344444840 scopus 로고    scopus 로고
    • Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement
    • Leung N, Griffin MD, Dispenzieri A, et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant. 2005;5(7):1660-1670.
    • (2005) Am J Transplant , vol.5 , Issue.7 , pp. 1660-1670
    • Leung, N.1    Griffin, M.D.2    Dispenzieri, A.3
  • 41
    • 0028970456 scopus 로고
    • Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
    • Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
    • (1995) Semin Hematol. , vol.32 , Issue.1 , pp. 45-59
    • Kyle, R.A.1    Gertz, M.A.2
  • 42
    • 0026519157 scopus 로고
    • Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989
    • Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
    • (1992) Blood , vol.79 , Issue.7 , pp. 1817-1822
    • Kyle, R.A.1    Linos, A.2    Beard, C.M.3    Linke, R.P.4    Gertz, M.A.5    O'Fallon, W.M.6    Kurland, L.T.7
  • 43
    • 79952139728 scopus 로고    scopus 로고
    • Outcome in renal AL amyloidosis after chemotherapy
    • Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 2011;29(6):674-681.
    • (2011) J Clin Oncol. , vol.29 , Issue.6 , pp. 674-681
    • Pinney, J.H.1    Lachmann, H.J.2    Bansi, L.3
  • 44
    • 4644336052 scopus 로고    scopus 로고
    • Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
    • Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757.
    • (2004) J Clin Oncol. , vol.22 , Issue.18 , pp. 3751-3757
    • Dispenzieri, A.1    Gertz, M.A.2    Kyle, R.A.3
  • 45
    • 84860643971 scopus 로고    scopus 로고
    • Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    • Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995.
    • (2012) J Clin Oncol. , vol.30 , Issue.9 , pp. 989-995
    • Kumar, S.1    Dispenzieri, A.2    Lacy, M.Q.3
  • 46
    • 2342525940 scopus 로고    scopus 로고
    • Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress
    • Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008-1010.
    • (2004) Circ Res. , vol.94 , Issue.8 , pp. 1008-1010
    • Brenner, D.A.1    Jain, M.2    Pimentel, D.R.3
  • 47
    • 77749251993 scopus 로고    scopus 로고
    • Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway
    • Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 2010;107(9):4188-4193.
    • (2010) Proc Natl Acad Sci USA. , vol.107 , Issue.9 , pp. 4188-4193
    • Shi, J.1    Guan, J.2    Jiang, B.3
  • 48
    • 78149291059 scopus 로고    scopus 로고
    • The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
    • Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430.
    • (2010) Blood , vol.116 , Issue.18 , pp. 3426-3430
    • Palladini, G.1    Barassi, A.2    Klersy, C.3
  • 49
    • 40849139507 scopus 로고    scopus 로고
    • Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
    • Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298.
    • (2008) Haematologica. , vol.93 , Issue.2 , pp. 295-298
    • Wechalekar, A.D.1    Lachmann, H.J.2    Offer, M.3    Hawkins, P.N.4    Gillmore, J.D.5
  • 50
    • 70349575412 scopus 로고    scopus 로고
    • Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study
    • VELCADE CAN2007 Study Group
    • Reece DE, Sanchorawala V, Hegenbart U, et al; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-1497.
    • (2009) Blood , vol.114 , Issue.8 , pp. 1489-1497
    • Reece, D.E.1    Sanchorawala, V.2    Hegenbart, U.3
  • 51
    • 77949897868 scopus 로고    scopus 로고
    • Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis
    • Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
    • (2010) J Clin Oncol. , vol.28 , Issue.6 , pp. 1031-1037
    • Kastritis, E.1    Wechalekar, A.D.2    Dimopoulos, M.A.3
  • 52
    • 79960934028 scopus 로고    scopus 로고
    • Efficacy and safety of once-weekly and twiceweekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study
    • Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twiceweekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
    • (2011) Blood , vol.118 , Issue.4 , pp. 865-873
    • Reece, D.E.1    Hegenbart, U.2    Sanchorawala, V.3
  • 53
    • 84860897399 scopus 로고    scopus 로고
    • Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
    • Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390.
    • (2012) Blood , vol.119 , Issue.19 , pp. 4387-4390
    • Venner, C.P.1    Lane, T.2    Foard, D.3
  • 54
    • 84860898706 scopus 로고    scopus 로고
    • Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    • Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide- bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
    • (2012) Blood , vol.119 , Issue.19 , pp. 4391-4394
    • Mikhael, J.R.1    Schuster, S.R.2    Jimenez-Zepeda, V.H.3
  • 55
    • 33846263334 scopus 로고    scopus 로고
    • Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
    • Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464.
    • (2007) Blood , vol.109 , Issue.2 , pp. 457-464
    • Wechalekar, A.D.1    Goodman, H.J.2    Lachmann, H.J.3    Offer, M.4    Hawkins, P.N.5    Gillmore, J.D.6
  • 56
    • 80054844341 scopus 로고    scopus 로고
    • Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients
    • Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346-4352.
    • (2011) Blood , vol.118 , Issue.16 , pp. 4346-4352
    • Cibeira, M.T.1    Sanchorawala, V.2    Seldin, D.C.3
  • 57
    • 84870699271 scopus 로고    scopus 로고
    • Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis
    • Cordes S, Dispenzieri A, Lacy MQ, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012;118(24):6105-6109.
    • (2012) Cancer. , vol.118 , Issue.24 , pp. 6105-6109
    • Cordes, S.1    Dispenzieri, A.2    Lacy, M.Q.3
  • 58
    • 34548567815 scopus 로고    scopus 로고
    • Immunoglobulin light (heavy) - Chain deposition disease: From molecular medicine to pathophysiology-driven therapy
    • Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy) - chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1(6):1342-1350.
    • (2006) Clin J Am Soc Nephrol. , vol.1 , Issue.6 , pp. 1342-1350
    • Ronco, P.1    Plaisier, E.2    Mougenot, B.3    Aucouturier, P.4
  • 61
    • 10744228129 scopus 로고    scopus 로고
    • Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors
    • Pozzi C, D'Amico, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154-1163.
    • (2003) Am J Kidney Dis. , vol.42 , Issue.6 , pp. 1154-1163
    • Pozzi, C.1    D'Amico2    Fogazzi, G.B.3
  • 62
    • 0027443918 scopus 로고
    • Brief report: Heavy-chain deposition disease
    • Aucouturier P, Khamlichi AA, Touchard G, et al. Brief report: heavy-chain deposition disease. N Engl J Med. 1993;329(19):1389-1393.
    • (1993) N Engl J Med. , vol.329 , Issue.19 , pp. 1389-1393
    • Aucouturier, P.1    Khamlichi, A.A.2    Touchard, G.3
  • 63
    • 0033012790 scopus 로고    scopus 로고
    • Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C (H) 1
    • Moulin B, Deret S, Mariette X, et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C (H) 1. J Am Soc Nephrol. 1999;10(3):519-528.
    • (1999) J Am Soc Nephrol. , vol.10 , Issue.3 , pp. 519-528
    • Moulin, B.1    Deret, S.2    Mariette, X.3
  • 64
    • 1642561684 scopus 로고    scopus 로고
    • High dose chemotherapy in light chain or light and heavy chain deposition disease
    • Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65(2):642-648.
    • (2004) Kidney Int. , vol.65 , Issue.2 , pp. 642-648
    • Royer, B.1    Arnulf, B.2    Martinez, F.3
  • 65
    • 78649879391 scopus 로고    scopus 로고
    • Resolution of mesangial light chain deposits 3 years after highdose melphalan with autologous peripheral blood stem cell transplantation
    • Harada K, Akai Y, Sakan H, Yamaguchi Y, Nakatani K, Iwano M, Saito Y. Resolution of mesangial light chain deposits 3 years after highdose melphalan with autologous peripheral blood stem cell transplantation. Clin Nephrol. 2010;74(5):384-388.
    • (2010) Clin Nephrol. , vol.74 , Issue.5 , pp. 384-388
    • Harada, K.1    Akai, Y.2    Sakan, H.3    Yamaguchi, Y.4    Nakatani, K.5    Iwano, M.6    Saito, Y.7
  • 66
    • 4444336030 scopus 로고    scopus 로고
    • Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation
    • Firkin F, Hill PA, Dwyer K, Gock H. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis. 2004;44(3):551-555.
    • (2004) Am J Kidney Dis. , vol.44 , Issue.3 , pp. 551-555
    • Firkin, F.1    Hill, P.A.2    Dwyer, K.3    Gock, H.4
  • 67
    • 33747359962 scopus 로고    scopus 로고
    • Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation
    • Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38(5):339-343.
    • (2006) Bone Marrow Transplant , vol.38 , Issue.5 , pp. 339-343
    • Weichman, K.1    Dember, L.M.2    Prokaeva, T.3
  • 68
    • 44449101706 scopus 로고    scopus 로고
    • Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    • Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23(6):2052-2057.
    • (2008) Nephrol Dial Transplant , vol.23 , Issue.6 , pp. 2052-2057
    • Lorenz, E.C.1    Gertz, M.A.2    Fervenza, F.C.3
  • 69
    • 53149102403 scopus 로고    scopus 로고
    • High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
    • Hassoun H, Flombaum C, D'Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant. 2008;42(6):405-412.
    • (2008) Bone Marrow Transplant , vol.42 , Issue.6 , pp. 405-412
    • Hassoun, H.1    Flombaum, C.2    D'Agati, V.D.3
  • 70
    • 85027921644 scopus 로고    scopus 로고
    • High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease
    • Telio D, Shepherd J, Forrest D, Zypchen L, Barnett M, Nevill T, Song KW. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant. 2012;47(3):453-455.
    • (2012) Bone Marrow Transplant , vol.47 , Issue.3 , pp. 453-455
    • Telio, D.1    Shepherd, J.2    Forrest, D.3    Zypchen, L.4    Barnett, M.5    Nevill, T.6    Song, K.W.7
  • 71
    • 84862906773 scopus 로고    scopus 로고
    • Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease
    • Brioli A, Zamagni E, Pasquali S, et al. Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. Bone Marrow Transplant. 2012;47(9):1248-1249.
    • (2012) Bone Marrow Transplant , vol.47 , Issue.9 , pp. 1248-1249
    • Brioli, A.1    Zamagni, E.2    Pasquali, S.3
  • 73
    • 71249133379 scopus 로고    scopus 로고
    • Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: A case report
    • Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc. 2009;41(10):4407-4410.
    • (2009) Transplant Proc. , vol.41 , Issue.10 , pp. 4407-4410
    • Kaposztas, Z.1    Kahan, B.D.2    Katz, S.M.3    Van Buren, C.T.4    Cherem, L.5
  • 74
    • 84864002302 scopus 로고    scopus 로고
    • Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure
    • Gharwan H, Truica CI. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol. 2012;29(2):1197-1201.
    • (2012) Med Oncol. , vol.29 , Issue.2 , pp. 1197-1201
    • Gharwan, H.1    Truica, C.I.2
  • 75
    • 84866355112 scopus 로고    scopus 로고
    • Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease
    • Tovar N, Cibeira MT, Rosiñol L, et al. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol. 2012;89(4):340-344.
    • (2012) Eur J Haematol. , vol.89 , Issue.4 , pp. 340-344
    • Tovar, N.1    Cibeira, M.T.2    Rosiñol, L.3
  • 76
    • 84864000088 scopus 로고    scopus 로고
    • Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy
    • Jimenez-Zepeda VH, Trudel S, Winter A, Reece DE, Chen C, Kukreti V. Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy. Am J Hematol. 2012;87(8):822-823.
    • (2012) Am J Hematol. , vol.87 , Issue.8 , pp. 822-823
    • Jimenez-Zepeda, V.H.1    Trudel, S.2    Winter, A.3    Reece, D.E.4    Chen, C.5    Kukreti, V.6
  • 77
    • 76249096571 scopus 로고    scopus 로고
    • How I treat multiple myeloma in younger patients
    • Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-5443.
    • (2009) Blood , vol.114 , Issue.27 , pp. 5436-5443
    • Stewart, A.K.1    Richardson, P.G.2    San-Miguel, J.F.3
  • 79
    • 0016262898 scopus 로고
    • Biologic and clinical significance of cryoglobulins. A report of 86 cases
    • Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788.
    • (1974) Am J Med. , vol.57 , Issue.5 , pp. 775-788
    • Brouet, J.C.1    Clauvel, J.P.2    Danon, F.3    Klein, M.4    Seligmann, M.5
  • 80
    • 0034893180 scopus 로고    scopus 로고
    • Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center
    • Trejo O, Ramos-Casals M, Garćia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80(4):252-262.
    • (2001) Medicine (Baltimore) , vol.80 , Issue.4 , pp. 252-262
    • Trejo, O.1    Ramos-Casals, M.2    Garćia-Carrasco, M.3
  • 81
    • 13344282086 scopus 로고    scopus 로고
    • Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy
    • Papo T, Musset L, Bardin T, et al. Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy. Arthritis Rheum. 1996;39(2):335-340.
    • (1996) Arthritis Rheum. , vol.39 , Issue.2 , pp. 335-340
    • Papo, T.1    Musset, L.2    Bardin, T.3
  • 82
    • 67649669575 scopus 로고    scopus 로고
    • Renal disease in cryoglobulinemic vasculitis
    • Mason JC, Pusey CD, eds, Amsterdam, Boston: Elsevier
    • Bridoux F, Sirac C, Jaccard A, et al. Renal Disease in Cryoglobulinemic Vasculitis. In: Mason JC, Pusey CD, eds. The kidney in systemic autoimmune diseases. Amsterdam, Boston: Elsevier; 2008:215-240.
    • (2008) The Kidney in Systemic Autoimmune diseases. , pp. 215-240
    • Bridoux, F.1    Sirac, C.2    Jaccard, A.3
  • 83
    • 0036840214 scopus 로고    scopus 로고
    • Renal involvement in monoclonal (type I) cryoglobulinemia: Two cases associated with IgG3 kappa cryoglobulin
    • Karras A, Noël LH, Droz D, et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis. 2002;40(5):1091-1096.
    • (2002) Am J Kidney Dis. , vol.40 , Issue.5 , pp. 1091-1096
    • Karras, A.1    Noël, L.H.2    Droz, D.3
  • 84
    • 84879167734 scopus 로고    scopus 로고
    • Type I cryoglobulinemia in multiple myeloma, a rare entity: Analysis of clinical and biological characteristics of seven cases and review of the literature
    • Payet J, Livartowski J, Kavian N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54(4):767-777.
    • (2013) Leuk Lymphoma. , vol.54 , Issue.4 , pp. 767-777
    • Payet, J.1    Livartowski, J.2    Kavian, N.3
  • 86
    • 0025786468 scopus 로고
    • Association between hepatitis C virus and mixed cryoglobulinemia [see comment]
    • Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. [see comment] Clin Exp Rheumatol. 1991;9(6):621-624.
    • (1991) Clin Exp Rheumatol. , vol.9 , Issue.6 , pp. 621-624
    • Ferri, C.1    Greco, F.2    Longombardo, G.3
  • 87
    • 33750307456 scopus 로고    scopus 로고
    • Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia
    • Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101-2108.
    • (2006) Arch Intern Med. , vol.166 , Issue.19 , pp. 2101-2108
    • Saadoun, D.1    Sellam, J.2    Ghillani-Dalbin, P.3    Crecel, R.4    Piette, J.C.5    Cacoub, P.6
  • 89
    • 77955857269 scopus 로고    scopus 로고
    • Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia
    • Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334.
    • (2010) Blood , vol.116 , Issue.3 , pp. 326-334
    • Saadoun, D.1    Rigon, M.R.2    Sene, D.3
  • 90
    • 77954869956 scopus 로고    scopus 로고
    • Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: A long-term study
    • Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-353.
    • (2010) Blood , vol.116 , Issue.3 , pp. 343-353
    • Dammacco, F.1    Tucci, F.A.2    Lauletta, G.3
  • 91
    • 84862732615 scopus 로고    scopus 로고
    • Management of noninfectious mixed cryoglobulinemia vasculitis: Data from 242 cases included in the CryoVas survey
    • Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996-6004.
    • (2012) Blood , vol.119 , Issue.25 , pp. 5996-6004
    • Terrier, B.1    Krastinova, E.2    Marie, I.3
  • 92
    • 84869426735 scopus 로고    scopus 로고
    • Immunotactoid glomerulopathy: Clinicopathologic and proteomic study
    • Nasr SH, Fidler ME, Cornell LD, et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant. 2012;27(11):4137-4146.
    • (2012) Nephrol Dial Transplant , vol.27 , Issue.11 , pp. 4137-4146
    • Nasr, S.H.1    Fidler, M.E.2    Cornell, L.D.3
  • 93
    • 23044460119 scopus 로고    scopus 로고
    • Glomerulopathy with non-organized and non-Randall type monoclonal immunoglobulin deposits A rare entity [Abstract]
    • Abstract 492
    • Bridoux F, Binaut R, G. Z, et al. Glomerulopathy with non-organized and non-Randall type monoclonal immunoglobulin deposits A rare entity [Abstract]. J Am Soc Nephrol. 2001;12(9):94a. Abstract 492.
    • (2001) J Am Soc Nephrol. , vol.12 , Issue.9
    • Bridoux, F.1    Binaut, R.G.Z.2
  • 94
    • 0347992788 scopus 로고    scopus 로고
    • Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immunecomplex glomerulonephritis
    • Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immunecomplex glomerulonephritis. Kidney Int. 2004;65(1):85-96.
    • (2004) Kidney Int. , vol.65 , Issue.1 , pp. 85-96
    • Nasr, S.H.1    Markowitz, G.S.2    Stokes, M.B.3
  • 95
    • 69849086679 scopus 로고    scopus 로고
    • Proliferative glomerulonephritis with monoclonal IgG deposits
    • Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055-2064.
    • (2009) J Am Soc Nephrol. , vol.20 , Issue.9 , pp. 2055-2064
    • Nasr, S.H.1    Satoskar, A.2    Markowitz, G.S.3
  • 96
    • 79960338674 scopus 로고    scopus 로고
    • Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: Correlation with IgG subclass and response to rituximab
    • Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6(7):1609-1616.
    • (2011) Clin J Am Soc Nephrol. , vol.6 , Issue.7 , pp. 1609-1616
    • Guiard, E.1    Karras, A.2    Plaisier, E.3
  • 98
    • 3042756207 scopus 로고    scopus 로고
    • Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    • Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004;104(1):40-42.
    • (2004) Blood , vol.104 , Issue.1 , pp. 40-42
    • Ma, C.X.1    Lacy, M.Q.2    Rompala, J.F.3
  • 99
    • 17144454246 scopus 로고    scopus 로고
    • Kappa light chain-associated Fanconi's syndrome: Molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals
    • Déret S, Denoroy L, Lamarine M, et al. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng. 1999;12(4):363-369.
    • (1999) Protein Eng. , vol.12 , Issue.4 , pp. 363-369
    • Déret, S.1    Denoroy, L.2    Lamarine, M.3
  • 100
    • 20144388799 scopus 로고    scopus 로고
    • Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia
    • Bridoux F, Sirac C, Hugue V, et al. Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis. 2005;45(4):749-757.
    • (2005) Am J Kidney Dis. , vol.45 , Issue.4 , pp. 749-757
    • Bridoux, F.1    Sirac, C.2    Hugue, V.3
  • 101
    • 0036720517 scopus 로고    scopus 로고
    • Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: Molecular analysis of a disorder with rapid clinical course and review of the literature
    • Lebeau A, Zeindl-Eberhart E, Müller EC, Müller-Höcker J, Jungblut PR, Emmerich B, Löhrs U. Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. Blood. 2002;100(5):1817- 1827.
    • (2002) Blood , vol.100 , Issue.5 , pp. 1817-1827
    • Lebeau, A.1    Zeindl-Eberhart, E.2    Müller, E.C.3    Müller-Höcker, J.4    Jungblut, P.R.5    Emmerich, B.6    Löhrs, U.7
  • 102
    • 77956246123 scopus 로고    scopus 로고
    • Crystal-storing histiocytosis with renal Fanconi syndrome: Pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome
    • El Hamel C, Thierry A, Trouillas P, et al. Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome. Nephrol Dial Transplant. 2010;25(9):2982-2990.
    • (2010) Nephrol Dial Transplant , vol.25 , Issue.9 , pp. 2982-2990
    • El Hamel, C.1    Thierry, A.2    Trouillas, P.3
  • 103
    • 84862497961 scopus 로고    scopus 로고
    • How I treat POEMS syndrome
    • Dispenzieri A. How I treat POEMS syndrome. Blood. 2012;119(24):5650-5658.
    • (2012) Blood , vol.119 , Issue.24 , pp. 5650-5658
    • Dispenzieri, A.1
  • 104
    • 80052573272 scopus 로고    scopus 로고
    • Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: A fortuitous association?
    • Bridoux F, Desport E, Frémeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9):2165-2174.
    • (2011) Clin J Am Soc Nephrol. , vol.6 , Issue.9 , pp. 2165-2174
    • Bridoux, F.1    Desport, E.2    Frémeaux-Bacchi, V.3
  • 105
    • 77958488596 scopus 로고    scopus 로고
    • Dense deposit disease associated with monoclonal gammopathy of undetermined significance
    • Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977-982.
    • (2010) Am J Kidney Dis. , vol.56 , Issue.5 , pp. 977-982
    • Sethi, S.1    Sukov, W.R.2    Zhang, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.